<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="pmc">IJPsy</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21430805</article-id><article-id pub-id-type="pmc">2963837</article-id><article-id pub-id-type="publisher-id">IJPsy-41-325</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A COMPARATIVE EFFICACY STUDY OF CENTBUTINDOLE AND HALOPERIDOL IN SCHIZOPHRENIA</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Harjeet</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Srivastava</surname><given-names>J.S.</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Raghuvanshi</surname><given-names>Charu</given-names></name><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Dalal</surname><given-names>P.K.</given-names></name><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name><surname>Asthana</surname><given-names>O.P.</given-names></name><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff id="aff1"><label>*</label>HARJEET SINGH, MD., Professor, Department of Psychiatry, K.G.'s Medical College, Lucknow.</aff><aff id="aff2">J.S. SRIVASTAVA, MD., DM., Scientist, Division of Cinical &#x00026; Experimental Medicine, C.D.R.I., Lucknow.</aff><aff id="aff3">CHARU RAGHUVANSHI, MBBS., Department of of Psychiatry, KG&#x02032;s Medical College, Lucknow.</aff><aff id="aff4">P.K. DALAL, MD., Professor, Department of of Psychiatry, KG&#x02032;s Medical College, Lucknow.</aff><aff id="aff5">O.P. ASTHANA, MD., D.Ch., Head, Division of Cinical &#x00026; Experimental Medicine, C.D.R.I., Lucknow.</aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence</bold></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>1999</year></pub-date><volume>41</volume><issue>4</issue><fpage>325</fpage><lpage>328</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Psychiatry</copyright-statement><copyright-year>1999</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>A double blind study was undertaken to compare the efficacy between centbutindole and haloperidol. A total of 44 patients suffering from schizophrenia diagnosed in accordance to ICD-10 criteria were included. They were randomly assigned into two groups receiving centbutindole (4.5 mg) or haloperidol (15 mg) in two divided doses per day for six weeks. Each patient was evaluated on Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale (CGI-S) and UKU side effect scale every week. Five patients (1 patient in centbutindole group, 4 patients in haloperidol group) dropped out due to various reasons. A total of 39 patients (21 patients in centbutindole group and 18 patients in haloperidol group) completed the study. The results revealed an early onset of therapeutic effect with centbutindole for both positive and negative symptoms. However, the efficacy was comparable between centibutindole and haloperidol from 3rd week onwards.</p></abstract><kwd-group><kwd>Centbutindole</kwd><kwd>schizophrenia</kwd><kwd>antipsychotic</kwd><kwd>haloperidol</kwd></kwd-group></article-meta></front></article>